Ventyx Biosciences
Dr. Kimball is CEO and President of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, a large academic multi-specialty group that includes Harvard Medical School faculty. A Professor of Dermatology at Harvard Medical School, Dr. Kimball’s research includes psoriasis and hidradenitis suppurativa. She has published over 340 papers, conducted over 150 clinical trials, has extensive experience in drug development, and was recognized by Fierce HealthCare with a Women of Influence Award in 2020. Dr. Kimball received her MD from the Yale School of Medicine, her MPH from the Johns Hopkins Bloomberg School of Public Health, and her bachelor's degree in molecular biology and public and international affairs from Princeton University.
This person is not in the org chart
This person is not in any offices
Ventyx Biosciences
1 followers
Ventyx Biosciences is a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high-value targets. Ventyx now includes combined assets from three separate companies: Oppilan Pharma, targeting S1P1R, Zomagen Biosciences, targeting NLRP3 and the inflammasome, and Ventyx Biosciences, targeting TYK2.